Indivior
Manufacturing · Virginia, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
10710 Midlothian Tpke Ste 125, North Che...Phone Number
(804) 379-1090Website
www.indivior.comRevenue
$1.3 BillionStock Symbol
INDVIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
1
1
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company was incorporated in 2014 and is headquartered in Richmond,...Explore more
Indivior Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Indivior your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Indivior is spiking on competitors!
Funding: Get notified immidiatlly once Indivior has new funding data
Congratulate Masked Content for being promoted to Masked Content at Indivior
Check if Indivior has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Indivior launches new products
Indivior, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Indivior had a recent Job posting/layoffs
Earning: See what the market has to say on Indivior recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Indivior as Masked Content
Find 3 more new buyers
Compare Similar Companies to Indivior
Compare insights from companies similar to Indivior, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Indivior is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Indivior is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Indivior.
Indivior Tech Stack
A closer look at the technologies used by Indivior
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Open Position
Open Position
Project
Indivior has executed a $175 million accelerated share repurchase program as part of its capital allocation strategy, citing a meaningful disconnect between the company's intrinsic value and its current share price.
Spending/Investment, Share Placement, Finance
Project
Business Development, Acquisitions
Indivior News & Media
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior Pharmaceuticals Inc. (NASDAQ:INDV) reported better-than-expected second-quarter 2026 results on Monday, driven by record sales of its opioid use disorder treatment SUBLOCADE, while raising its full-year financial guidance.Supernus Announces Second Quarter 2026 Financial Results
ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2026 and associated Company developments.Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
• Q2’26 Total Net Revenue of $343 Million, Up 14% YoYSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company with significant scale. The transaction is expected to generate significant value for stockholders of both companies,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Indivior
Sign Up For FreeTo access detailed company insights
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE subli... Read More
